Loading…
Maspin expression in stage I and II oral tongue squamous cell carcinoma
Background A relatively high failure rate in the therapy of patients with early oral tongue squamous cell carcinomas (SCCs) is evidenced by untreated clinically negative neck lymph node metastasis. It is important to predict the malignant potential of oral tongue SCC in stage I and II patients, beca...
Saved in:
Published in: | Head & neck 2001-11, Vol.23 (11), p.962-966 |
---|---|
Main Authors: | , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Background
A relatively high failure rate in the therapy of patients with early oral tongue squamous cell carcinomas (SCCs) is evidenced by untreated clinically negative neck lymph node metastasis. It is important to predict the malignant potential of oral tongue SCC in stage I and II patients, because the development of lymph node metastasis directly affects the prognosis of the patients.
Methods
We evaluated maspin expression immunohistochemically in patients with stage I and II oral tongue SCCs and determined whether the expression level may be a useful factor in predicting metastatic potential and prognosis of these SCCs.
Results
Clinical follow‐up data showed a longer disease‐free interval and overall survival periods for tumors immunohistochemically positive for maspin than for tumors negative for maspin, with the difference in disease‐free interval being statistically significant (p = .01). The absence of maspin expression was found more frequently in cases of subsequent cervical lymph node metastasis than in cases without metastasis (p = .03).
Conclusions
Decreased maspin expression may be a significant factor associated with the metastatic potential of stage I and II oral tongue SCCs. © 2001 John Wiley & Sons, Inc. Head Neck 23: 962–966, 2001. |
---|---|
ISSN: | 1043-3074 1097-0347 |
DOI: | 10.1002/hed.1139 |